Alvaro Gomez Gonzalez

About me
Publications
Public outreach and news

Research

The general aim of my doctoral project is to optimise the use of current therapeutic strategies in patients with systemic lupus erythematosus. My project has two main branches: (i) to identify demographical, clinical and immunological factors that influence the efficacy of current therapies, with special focus on biologics targeting B cells
(ii) to determine the impact of pharmacological and non-pharmacological factors on patient’s health-related quality of life. Furthermore, we study the performance of different composite outcomes as well as patient reported outcomes in clinical trial settings.

Articles

Article: RHEUMATOLOGY INTERNATIONAL. 2024;44(5):851-861
Obesity and tobacco smoking are independently associated with poor patient-reported outcomes in SLE: a cross-sectional study
Gomez A; Parodis I; Sjowall C
Article: LUPUS. 2024;33(6):615-628
Factors associated with non-adherence to medications in systemic lupus erythematosus: Results from a Swedish survey
Emamikia S; Gomez A; Adahl T; von Perner G; Enman Y; Chatzidionysiou K; Arkema EV; Parodis I
Article: RHEUMATOLOGY. 2024;63(2):338-348
Belimumab and antimalarials combined against renal flares in patients treated for extra-renal systemic lupus erythematosus: results from 4 phase III clinical trials
Gomez A; Jagerback S; Sjowall C; Parodis I
Article: RHEUMATOLOGY. 2024;:keae023
Predictors of renal flares in systemic lupus erythematosus: a post-hoc analysis of four phase III clinical trials of belimumab
Jagerback S; Gomez A; Parodis I
Article: RHEUMATOLOGY. 2023;62(12):3916-3923
Sensitivity analysis of EQ-5D-3L index scores in terms of discriminative and known-groups validity in SLE: introducing Adequate Health State
Hua N; Gomez A; Lindblom J; Emamikia S; Enman Y; Grannas D; Heintz E; Regardt M; Parodis I
Article: FRONTIERS IN MEDICINE. 2023;10:1247354
Obesity is associated with pain and impaired mobility despite therapy in systemic lupus erythematosus
Borg A; Lindblom J; Gomez A; Soltani A; Enman Y; Heintz E; Regardt M; Grannas D; Emamikia S; Parodis I
Article: RHEUMATOLOGY. 2022;61(12):4752-4762
Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosus
Emamikia S; Oon S; Gomez A; Lindblom J; Borg A; Enman Y; Morand E; Grannas D; van Vollenhoven RF; Nikpour M; Parodis I
Article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022;23(22):13941
B Cell Kinetics upon Therapy Commencement for Active Extrarenal Systemic Lupus Erythematosus in Relation to Development of Renal Flares: Results from Three Phase III Clinical Trials of Belimumab
Parodis I; Gomez A; Lindblom J; Chow JW; Sjowall C; Sciascia S; Gatto M
Article: AUTOIMMUNITY REVIEWS. 2022;21(11):103188
Do biological agents improve health-related quality of life in patients with systemic lupus erythematosus? Results from a systematic search of the literature
Gomez A; Parodis I
Article: FRONTIERS IN MEDICINE. 2022;9:852162
Early Changes in B and Plasma Cell Subsets and Traditional Serological Markers as Predictors of SRI-4 Response to Therapy in Systemic Lupus Erythematosus
Parodis I; Gomez A; Lindblom J; Chow JW; Doria A; Gatto M
Article: FRONTIERS IN MEDICINE. 2022;9:1092325
EQ-5D full health state after therapy heralds reduced hazard to accrue subsequent organ damage in systemic lupus erythematosus
Lindblom J; Zetterberg S; Emamikia S; Borg A; von Perner G; Enman Y; Heintz E; Regardt M; Grannas D; Gomez A; Parodis I
Article: FRONTIERS IN IMMUNOLOGY. 2022;13:796508
Early B Cell and Plasma Cell Kinetics Upon Treatment Initiation Portend Flares in Systemic Lupus Erythematosus: A Post-Hoc Analysis of Three Phase III Clinical Trials of Belimumab
Parodis I; Gomez A; Chow JW; Borg A; Lindblom J; Gatto M
Article: RHEUMATOLOGY. 2021;60(10):4703-4716
EQ-5D-3L full health state discriminates between drug and placebo in clinical trials of systemic lupus erythematosus
Lindblom J; Gomez A; Borg A; Emamikia S; Ladakis D; Matilla J; Pehr M; Cobar F; Enman Y; Heintz E; Regardt M; Parodis I
Article: RHEUMATOLOGY. 2021;60(9):4205-4217
Contribution of abnormal BMI to adverse health-related quality of life outcomes after a 52-week therapy in patients with SLE
Borg A; Gomez A; Cederlund A; Cobar F; Qiu V; Lindblom J; Emamikia S; Enman Y; Pettersson S; Parodis I
Article: RHEUMATOLOGY. 2021;60(3):1260-1272
Impact of overweight and obesity on patient-reported health-related quality of life in systemic lupus erythematosus
Gomez A; Butrus FH; Johansson P; Akerstrom E; Soukka S; Emamikia S; Enman Y; Pettersson S; Parodis I
Article: FRONTIERS IN MEDICINE. 2021;8:651249
Adverse Health-Related Quality of Life Outcome Despite Adequate Clinical Response to Treatment in Systemic Lupus Erythematosus
Gomez A; Qiu V; Cederlund A; Borg A; Lindblom J; Emamikia S; Enman Y; Lampa J; Parodis I
Article: RHEUMATOLOGY. 2020;59(11):3424-3434
Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis
Parodis I; Adamichou C; Aydin S; Gomez A; Demoulin N; Weinmann-Menke J; Houssiau FA; Tamirou F
Article: JOURNAL OF CLINICAL MEDICINE. 2020;9(6):E1813-1813
Use of Antimalarial Agents Is Associated with Favourable Physical Functioning in Patients with Systemic Lupus Erythematosus
Gomez A; Soukka S; Johansson P; Akerstrom E; Emamikia S; Enman Y; Chatzidionysiou K; Parodis I
Article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2020;21(10):E3463-3463
Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus
Parodis I; Akerstrom E; Sjowall C; Sohrabian A; Jonsen A; Gomez A; Frodlund M; Zickert A; Bengtsson AA; Roennelid J; Gunnarsson I
Article: RHEUMATOLOGY. 2019;58(12):2170-2176
Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus
Parodis I; Johansson P; Gomez A; Soukka S; Emamikia S; Chatzidionysiou K
Article: LANCET RHEUMATOLOGY. 2019;1(3):E163-E173
Definitions of remission in systemic lupus erythematosus: a post-hoc analysis of two randomised clinical trials
Parodis I; Emamikia S; Gomez A; Gentline C; Arkema EV; Chatzidionysiou K; van Vollenhoven RF
Article: EXPERT OPINION ON BIOLOGICAL THERAPY. 2019;19(2):157-168
Clinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studies
Parodis I; Emamikia S; Gomez A; Gunnarsson I; van Vollenhoven RF; Chatzidionysiou K
Article: EXPERT OPINION ON BIOLOGICAL THERAPY. 2018;18(8):911-920
Smoking reduces the efficacy of belimumab in mucocutaneous lupus
Parodis I; Gomez A; Frodlund M; Jonsen A; Zickert A; Sjowall C; Bengtsson AA; Gunnarsson I
Journal article: PLOS ONE. 2017;12(9):e0184189
Aged blood factors decrease cellular responses associated with delayed gingival wound repair
Paz Saldias M; Fernandez C; Morgan A; Diaz C; Morales D; Jana F; Gomez A; Silva A; Briceno F; Oyarzun A; Maldonado F; Cerda O; Smith PC; Caceres M
Show more

All other publications

Review: RHEUMATOLOGY INTERNATIONAL. 2024;44(5):765-778
Efficacy of lifestyle interventions in the management of systemic lupus erythematosus: a systematic review of the literature
Tsoi A; Gomez A; Bostroem C; Pezzella D; Chow JW; Girard-Guyonvarc'h C; Stamm T; Arnaud L; Parodis I
Review: RHEUMATOLOGY ADVANCES IN PRACTICE. 2024;8(2):rkae037
Lifestyle interventions in the management of systemic sclerosis: a systematic review of the literature
Parodis I; Tsoi A; Gomez A; Chow JW; Girard-Guyonvarc'h C; Stamm T; Bostrom C
Review: RMD OPEN. 2023;9(3):e003297
Systematic literature review informing the EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis
Parodis I; Gomez A; Tsoi A; Chow JW; Pezzella D; Girard C; Stamm TA; Bostrom C
Review: PATIENT RELATED OUTCOME MEASURES. 2023;14:1-13
Impact of Belimumab on Patient-Reported Outcomes in Systemic Lupus Erythematosus: Insights from Clinical Trials and Real-World Evidence
Gomez A; Enman Y; Parodis I
Letter: AUTOIMMUNITY REVIEWS. 2019;18(10):102372
Antimalarial agents diminish while methotrexate, azathioprine and mycophenolic acid increase BAFF levels in systemic lupus erythematosus
Hernandez-Breijo B; Gomez A; Soukka S; Johansson P; Parodis I
Letter: ANNALS OF THE RHEUMATIC DISEASES. 2019;78(7):1006-1007
Established organ damage reduces belimumab efficacy in systemic lupus erythematosus
Parodis I; Gomez A; Emamikia S; Chatzidionysiou K
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2019;78:777-778
ANTIMALARIAL AGENTS DIMINISH WHILE METHOTREXATE, AZATHIOPRINE AND MYCOPHENOLIC ACID INCREASE BAFF LEVELS IN SYSTEMIC LUPUS ERYTHEMATOSUS
Hernandez-Breijo B; Gomez A; Soukka S; Johansson P; Parodis I
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2019;78:761
PREDICTORS OF LOW DISEASE ACTIVITY AND CLINICAL REMISSION FOLLOWING BELIMUMAB TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS
Parodis I; Johansson P; Gomez A; Soukka S; Emamikia S; Chatzidionysiou K
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2019;78:781-782
ANTIMALARIAL AGENTS IMPROVE PHYSICAL FUNCTIONING IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Parodis I; Soukka S; Gomez A; Enman Y; Johansson P; Emamikia S; Chatzidionysiou K

Research

Articles

All other publications

News from KI

Events from KI